Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects (Oberab)
This study aims to determine, in obese subjects, the antisecretory effect of a single dose of placebo, rabeprazole 20 mg and omeprazole 20 mg using 24h gastric pH monitoring, in a prospective, monocentre, randomized manner. Monitorings are separated between 6 and10 days. The main outcome criteria of analysis is the percentage of time with gastric pH above 3 during 24hours.
- In order to measure antisecretory effect, the main outcome criteria of analysis will be the percentage of time with gastric pH above 3 and measured during 24hours following rabeprazole administration in comparison with omeprazole administration.
|Study Start Date:||April 2010|
|Study Completion Date:||July 2010|
|Primary Completion Date:||July 2010 (Final data collection date for primary outcome measure)|
|Experimental: Omeprazole||Drug: Omeprazole|
|Experimental: Rabeprazole||Drug: Rabeprazole|
|Placebo Comparator: Placebo||Drug: Lactose|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01136317
|CHU de Nantes|
|Nantes, France, 44093|
|Principal Investigator:||Stanislas Bruley des Varannes, MD||CHU de Nantes|